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Background: Bone and mineral abnormalities, and cardiovascular calciﬁcation are asso-
ciated with increased cardiovascular mortality in patients with chronic kidney disease
(CKD). Recent studies have implicated Wnt  signaling pathway in the pathogenesis of bone
metabolism and vascular calciﬁcation. Sclerostin is a soluble inhibitor of Wnt  signaling
pathway and has been shown to be associated with decreased bone turnover and vascular
calciﬁcation in CKD patients.
Objectives: The aim was to investigate whether the circulating levels of sclerostin are asso-
ciated with all-cause mortality in prevalent hemodialysis patients.
Methods: Data are prospectively collected for 24 months for survival analysis in 350 prevalent
hemodialysis patients. At baseline, serum sclerostin levels were measured and arteriove-
nous ﬁstula calciﬁcation was detected by using a 64-detector computerized tomographic
scanner.
Results: During the follow-up, 84 (24%) patients died. Patients who died had higher serum
sclerostin levels. Kaplan–Meier curve revealed that patients with increasing tertiles of serum
sclerostin levels at baseline, had a worse survival. In the multivariate Cox regression analysis
age, albumin, and presence of arteriovenous ﬁstula calciﬁcation, but not sclerostin levels,
were found to be independent predictors of survival in maintenance hemodialysis patients.
Conclusion: Further clinical studies with longer follow-up are needed to clarify the impact of
serum sclerostin levels on morbidity and mortality of maintenance hemodialysis patients.
Clinical trial registration number: The study was performed as a post hoc survival analysis
of  the patients involved in a single-center prospective trial investigating the association
between serum sclerostin levels and arteriovenous ﬁstula calciﬁcation and patency [Balcı
M,  et al. Herz 2015;40:289–97] with a Clinicaltrials.gov number: NCT01382966.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
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Niveles  de  esclerostina  sérica,  calciﬁcación  de  la  fístula  arteriovenosa  y
mortalidad  por  todas  las  causas  a  los  2  an˜os  en  pacientes  en
hemodiálisis  prevalente
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Antecedentes: Algunas anomalías minerales óseas y la calciﬁcación cardiovascular están aso-
ciadas con un aumento en la mortalidad cardiovascular en pacientes con enfermedad renal
crónica (ERC). Estudios recientes han implicado a la vía de sen˜alización Wnt  en la patogenia
del  metabolismo óseo y la calciﬁcación vascular. La esclerostina es un inhibidor soluble de
la  vía de sen˜alización Wnt  y se ha demostrado que está relacionada con una reducción del
recambio óseo y de la calciﬁcación vascular en pacientes con ERC.
Objetivo: El objetivo fue investigar si los niveles circulantes de esclerostina están asociados
con  la mortalidad por todas las causas en pacientes en hemodiálisis prevalente.
Métodos: Se recogieron datos de manera prospectiva durante 24 meses para el análisis de
supervivencia en 350 pacientes en hemodiálisis prevalente. Al inicio del estudio se midieron
los  niveles de esclerostina sérica y se detectó calciﬁcación de la fístula arteriovenosa medi-
ante  el uso de un escáner tomográﬁco computarizado de 64 detectores.
Resultados: Durante el período de seguimiento, murieron 84 pacientes (24%). Los pacientes
que  murieron presentaban elevados niveles de esclerostina sérica. La curva de Kaplan–Meier
reveló que los pacientes con terciles en aumento de esclerostina sérica al inicio del estudio
tenían peores tasas de supervivencia. En el análisis de regresión de Cox multivariado, la
edad, los valores de albúmina y la existencia de calciﬁcación de la fístula arteriovenosa,
pero no los niveles de esclerostina, demostraron ser los indicadores independientes de
supervivencia en pacientes en hemodiálisis de mantenimiento.
Conclusión: Se necesitan más estudios clínicos con un seguimiento más  extenso para aclarar
el  impacto de los niveles de esclerostina sérica en la morbimortalidad de los pacientes en
hemodiálisis de mantenimiento.
Número de registro del ensayo clínico: El estudio se llevó a cabo como un análisis post hoc de
supervivencia de los pacientes involucrados en un ensayo prospectivo de un único centro,
que  investigaba la asociación entre niveles de esclerostina sérica y la calciﬁcación y per-
meabilidad de la fístula arteriovenosa [Balcı M, et al. Herz 2015;40:289–97], con el número
NCT01382966 en Clinicaltrials.gov.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
A growing body of evidence indicates that abnormalities of
bone and mineral metabolism in chronic kidney disease (CKD)
may contribute to the development of cardiovascular disease
and increased cardiovascular mortality, with the most likely
link being the development of vascular calciﬁcation.1,2 The
signaling pathways involved in these processes remain incom-
pletely understood.3,4
Sclerostin is a soluble inhibitor of Wnt/b-catenin (canon-
ical) signaling pathway.5 The main action of sclerostin is a
decrease in bone formation via inhibiting osteoblast prolifera-
tion and differentiation, and promoting osteoblast apoptosis.6
Recently, increased levels of sclerostin were shown to be asso-
ciated with decreased bone turnover and osteoblast number
in dialysis patients.7 On the other hand, sclerostin has been
demonstrated to be upregulated during vascular smooth mus-
cle cell calciﬁcation in vitro.8 It needs to be further explored
that whether the effects of sclerostin on bone turnover
and vascular tissue also translate into clinically signiﬁcant
changes.
The aim of the present prospective study was to investigate
the association of circulating concentrations of sclerostin and
all-cause mortality in maintenance hemodialysis patients,
due to limited data in this area.
Methods
Patients
The study protocol was performed according to the Dec-
laration of Helsinki and was approved by the local ethics
committee of Yuksek Ihtisas Training and Research Hospital,
Ankara, Turkey and all the patients provided written informed
consent before entering the study.
A post hoc survival analysis of the patients involved in
a single-center prospective trial investigating the association
between serum sclerostin levels and arteriovenous ﬁstula cal-
ciﬁcation and patency, was performed [Balcı M, et al. Herz
2015;40:289–97]. The study was done at the RFM Dialysis Cen-
ter, Ankara, Turkey between August 2011 and July 2013. The
exclusion criteria in that work were vascular access other
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than mature native forearm arteriovenous ﬁstula, a previous
history of intervention like percutaneous angioplasty and/or
stenting, a mature forearm arteriovenous ﬁstula unable to
provide spKt/V > 1.2 in a 4-h dialysis session, active infection,
active malignancy, active autoimmune disease, recent hospi-
talization or unstable hemodynamic status in the preceding 3
months, and patient refusal.
At August 1st 2011, 350 patients (155 women and 195
men, mean age 55 ± 10 years, mean hemodialysis vintage:
56 ± 23 months, on hemodialysis thrice a week for at least 6
months) had all work-up ﬁnished for the eligibility and alloca-
tion. The patients suffered from end stage renal disease due
to diabetic nephropathy (n = 124), hypertensive nephroscle-
rosis (n = 102), chronic glomerulonephritis (n = 77), chronic
pyelonephritis (n = 12) and polycystic disease (n = 15). The renal
diagnosis was unknown in 20 patients. Presence of resid-
ual renal function (RRF) was deﬁned as residual glomerular
ﬁltration rate ≥1 mL/min. Mean residual renal function was
0.7 ± 1.1 mL/min/1.73 m2.
All patients were ≥18 years of age and were receiving
conventional 4-h hemodialysis with synthetic polysulphone
dialysers F6HPS and F7HPS (Fresenius AG, Bad Homburg,
Germany) thrice a week, with bicarbonate dialysate, and low-
molecular-weight heparin for standard anticoagulation. Mean
blood ﬂow rate was 300 mL/min during the HD session (range
250–340 mL/min). Dialysate ﬂuid composition was sodium
140 mEq/L, potassium 2–3 mEq/L, calcium 3 mEq/L and bicar-
bonate 33 mEq/L. Targeted dialysis efﬁciency was based on
single pool Kt/V urea nitrogen (spKt/V) values according to the
National Kidney Foundation-Kidney Disease Outcomes Qual-
ity Initiative Guidelines.
Angiotensin-converting enzyme inhibitors (n = 44),
angiotensin receptor blockers (n = 66), beta-blockers (n = 82)
and calcium channel blockers (n = 76) were given for hyper-
tension management. Patients were prescribed treatments
including CaCO3 (32%), sevelamer-HCl (19%), Ca acetate (41%),
calcitriol (69%), anti-platelet agents (70%), warfarin (5%) and
erythropoietin (68%). The mean erythropoietin dose was
145 U/kg/week achieving a mean hemoglobin (Hb) serum level
of 11.2 g/dL; <10% of patients had serum Hb <10 g/dL. None
of the patients received calcimimetic, glucocorticoid, statin,
bisphosphonates or denosumab.
Clinical  parameters  and  biochemical  assays
Information regarding baseline demographic characteristics,
etiology of end stage renal disease, presence of diabetes
mellitus were collected by reviewing medical records. Car-
diovascular history was deﬁned as history of myocardial
infarction, percutaneous coronary artery intervention, cardiac
by-pass or valvular surgery, peripheral artery disease or stroke.
Venous blood samples were drawn after an overnight
fast. The blood sample was obtained directly through an
arteriovenous ﬁstula on a mid-week non-dialysis day. Bio-
chemical serum parameters (creatinine, blood urea nitrogen,
glucose, electrolytes, albumin and complete blood count cal-
cium, phosphate, lipids, protein, cholesterol, and triglycerides)
were performed by standard laboratory procedure using an
automated analyzer. Serum C-reactive protein (CRP) level
was detected by rate nephelometry (IMAGE). spKt/V value
was  calculated according to the Daugirdas second-generation
formula.9 Normalized protein catabolic rate (nPCR) was calcu-
lated as a measure of daily protein intake of patients.10
Outcome,  exposures  and  covariates
The primary outcome was 24-months, all-cause mortal-
ity. The primary exposure variable was the baseline serum
sclerostin level, measured at the initiation of outpatient
hemodialysis. Serum sclerostin level was measured by a
commercially available enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Minneapolis, MN)  according to the
manufacturer’s instructions and as used in previous studies
by Cejka et al.7,11 The intra-assay and inter-assay coefﬁcients
of variation were 7.5% and 6.3%, respectively. Patients were
classiﬁed in 3 groups according to value of baseline circulat-
ing sclerostin levels, corresponding to Group 1 (36–586 pg/ml),
Group 2 (587–1903 pg/ml) and Group 3 (1904–8822 pg/ml).
Serum intact parathormone and alkaline phosphatase lev-
els were studied by means of a computerized autoanalyser
(Hitachi 717; Boehringer-Mannheim). Serum was available for
radioimmunoassay of 25-dihydroxy vitamin D3 levels (Dia-
Sorin Corporation, Stillwater, MN) in all patients.
Multi-detector  spiral  computerized  tomography
A non-enhanced computed tomography (CT) was performed
to measure to arteriovenous ﬁstula calcium score on a 64-
detector CT scanner (Aquilion; Toshiba Medical Systems,
Tokyo, Japan) as a deputy marker of vascular calciﬁcation.
Foci of arteriovenous ﬁstula calciﬁcation was detected by
an experienced radiologist and scored using semi-automatic
commercial software (Vitrea 2, Vital images) by detection of
at least 3 contiguous pixels (voxel size: 1.03 mm3) of peak
density ≥130 Hounsﬁels Units (HU). The lesion score was cal-
culated with the area density method, by multiplying the
lesion area by a density factor derived from the maximal HU
within the area as described by Agatston.12 The density fac-
tor was assigned in the following manner: 1 for lesions whose
maximal density was 130–199 HU, 2 for lesions 200–299 HU, 3
for lesions 300–399 HU, and 4 for lesions >400 HU. Based on
these calculations, patients were divided into 2 groups as hav-
ing non-calciﬁed and calciﬁed arteriovenous ﬁstulas.
Statistical  analysis
Normally distributed continuous variables are presented as
mean ± standard deviation, and non-normally distributed
continuous variables are presented as median with 25th and
75th percentiles. Categorical data are presented as percent-
ages. To test for associations between serum sclerostin levels
and demographic, clinical and laboratory parameters, we
examined serum sclerostin levels in quartiles according to
the distribution of values in HD patients. Differences in clinical
and biochemical parameters were compared using analysis
of variance for continuous variables and chi-square test for
categorical variables, whereas non-parametric Kruskal–Wallis
test was used for non-normally distributed continuous vari-
ables. Spearman correlation coefﬁcients were obtained for
all potential predictor variables to look for confounding.
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Multivariate statistical analysis (logistic regression, enter
method) was used to account for possible confounders for
arteriovenous ﬁstula calciﬁcation. Kaplan–Meier survival
analysis was used to calculate cumulative incidence of the
all-cause mortality. Variables that affected all-cause mortality
(p < 0.2) in univariate analysis were then included in multi-
variate Cox proportional hazards models to determine risk
factors associated with all-cause mortality. Test results were
presented as hazard ratios with 95% conﬁdence intervals,
and a p-value of <0.05 was considered to be statistically
signiﬁcant. Data analysis was performed by using SPSS for
Windows, version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Association  of  baseline  characteristics  and  sclerostin
Mean serum sclerostin level in hemodialysis patients was
higher when compared to age- and gender-matched healthy
controls (1519 ± 1378 vs 128 ± 49 pg/ml, p < 0.0001). Sclerostin
levels were not signiﬁcantly different in patients with a posi-
tive history of hypertension (1520 ± 1479 vs 1506 ± 1480 pg/ml,
p = 0.870), dyslipidemia (1486 ± 1432 vs 1541 ± 1477, p = 0.576)
and smoking (1599 ± 1356 vs 1534 ± 1410, p = 0.690) compared
with those without. However, male patients had signiﬁ-
cantly higher serum sclerostin levels than female patients
(1736 ± 1109 vs 1212 ± 975 pg/ml, p = 0.025). Moreover, patients
with a positive cardiovascular history had higher serum lev-
els than patients with not (2008 ± 1635 vs 1431 ± 1307 pg/ml,
p = 0.018). Furthermore, patients with type 2 diabetes mellitus
(DM) tended to have higher sclerostin levels than patients with
not (1678 ± 1476 vs 1404 ± 1290 pg/ml, p = 0.071). No interaction
between the use of calcitriol and serum sclerostin levels was
found.
No signiﬁcant correlations were observed between serum
sclerostin levels and age, hemodialysis vintage, systolic and
diastolic blood pressure, LDL- and HDL-cholesterol, trigly-
cerides, hemoglobin, serum albumin, calcium, phosphate,
alkaline phosphatase, uric acid and CRP levels. However, scle-
rostin levels were negatively correlated with log serum intact
parathormone levels (r = −0.222, p = 0.005).
The demographic and clinical characteristics of the study
patients according to the sclerostin tertiles are depicted in
Table 1. Patients in the highest quartile had lower albumin
levels and log intact parathormone (Table 1), and higher fre-
quency of arteriovenous ﬁstula calciﬁcation on computerized
tomography and cardiovascular history (Table 1). No signiﬁ-
cant difference was noted for any other demographic, clinical
and laboratory variables (Table 1).
Arteriovenous  ﬁstula  calciﬁcation  and  serum  sclerostin
levels
Patients with arteriovenous ﬁstula calciﬁcation (Fig. 1) had
higher sclerostin levels than patients without (2564 ± 1841 vs
1063 ± 706 pg/ml, p < 0.0001). According to univariate logistic
regression analysis, diabetes mellitus, cardiovascular history,
treatment with calcium-based phosphate binders and scle-
rostin levels were signiﬁcant predictors for arteriovenous
ﬁstula calciﬁcation (Table 2). Increased age tended to inﬂuence
arteriovenous ﬁstula calciﬁcation among study patients. The
multivariate logistic regression analysis corrected for calcitriol
use revealed that presence of positive cardiovascular history,
treatment with calcium-based phosphate binders and lower
but not higher serum sclerostin levels predicted arteriovenous
ﬁstula calciﬁcation independently (Table 2).
Demographic  and  clinical  parameters  and  all-cause
mortality
Overall, 84 of 350 patients (24%) died during the 24-months
follow-up. When compared, patients who died were older
(55.9 ± 13 vs 55.9 ± 13 years, p = 0.022), had lower serum albu-
min  (3.71 ± 0.11 vs 3.9 ± 0.34 g/L, p = 0.030) and 25-hydroxy
vitamin D3 (11.2 ± 5 vs 15.8 ± 6 ng/mL, p = 0.010) and had higher
serum alkaline phosphatase levels (132 ± 28 vs 84 ± 34 U/L,
p = 0.03). Patients who died also had a tendency to have
lower hemoglobin (11.20 ± 1.20 vs 10.90 ± 0.96 g/dL, p = 0.069)
and log serum intact parathormone (2.01 ± 0.11 vs 2.27 ± 0.38,
p = 0.080). Gender, hemodialysis vintage, systolic and diastolic
blood pressure, spKt/V, serum levels of calcium, phosphate, C-
reactive protein, uric acid, LDL-cholesterol, HDL-cholesterol,
triglycerides, cardiovascular history, presence of diabetes mel-
litus and treatment with calcium-based phosphate binders
were not statistically different. However, patients who  had
arteriovenous ﬁstula calciﬁcation did have worse survival than
patients without (2 = 7.15; p = 0.007, log-rank test, Fig. 2).
Serum  sclerostin  level  and  all-cause  mortality
Patients who died had elevated serum sclerostin levels at
baseline compared to patients who survived at the end of
the 24-months follow-up (2143 ± 1327 vs 1469 ± 1373 pg/ml;
p = 0.017). Kaplan–Meier curve shows that study patients with
increasing serum sclerostin levels at baseline, had a worse sur-
vival (2 = 6.668; p = 0.036, log-rank test, Fig. 3). Using the Cox
proportional hazard model with multicovariate adjustments,
age, albumin, and presence of arteriovenous ﬁstula calciﬁca-
tion were found to be associated with survival in maintenance
hemodialysis patients (Table 3). Results were already corrected
for calcitriol use and were unaffected when serum sclerostin
level was considered as a continuous variable.
Discussion
Despite lower circulating sclerostin levels in patients who
survived, serum sclerostin levels were not an independent
predictor of survival in prevalent hemodialysis patients in this
work. Furthermore age, albumin and presence of arteriove-
nous ﬁstula calciﬁcation were found to be associated with
survival in maintenance hemodialysis patients.
What could be the reason that sclerostin was chosen and
studied as a candidate risk factor for mortality in preva-
lent hemodialysis patients? The osteocyte product sclerostin
is emerging as an important paracrine regulator of bone
metabolism. Sclerostin has been shown to play a key inhibitor
role in bone formation and consequently protects against the
deleterious effects of uncontrolled bone growth.13 Recently,
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Table 1 – Baseline demographic and clinical characteristics of patients according to serum sclerostin tertiles.
Parameter 1st Tertile
(36–586 pg/ml)
N = 115
2nd  Tertile
(587–1903 pg/ml)
N = 117
3rd  Tertile
(1904–8822 pg/ml)
N = 118
p  Value
Age (years) 52  ± 10 55 ± 10 57 ± 14 0.46
Women/Men (n) 57/58  48/69 50/68 0.36
Hemodialysis vintage (months) 59 ± 30 56 ± 25 53 ± 26 0.85
Diabetes (n, %) 50 (43.4%) 61 (52.1%) 49 (41.5%) 0.66
Cardiovascular history (n, %) 26 (22.6%) 39 (33.3%) 52 (44%) 0.01
Smoking (n, %) 24 (20.8%) 30 (25.6%) 38 (32.2%) 0.42
Arteriovenous ﬁstula calciﬁcation on computerized
tomography (n, %)
14  (12.1%) 35 (30%) 82 (69.4%) <0.0001
Residual renal function (mL/min/1.73 m2) 0.70 ± 1.1 0.72 ± 1.2 0.68 ± 1.5 0.46
Ultraﬁltration (kg/dialysis session) 2.9 ± 1.0 3.0 ± 1.0 2.9 ± 1.2 0.77
AV ﬁstula ﬂow (mL/min) 280 ± 85 283 ± 77 291 ± 65 0.43
BMI (kg/m2) 22.2±  2.9 21.5 ± 3.1 20.6 ± 3.9 0.55
Systolic BP (mm Hg) 112 ± 18 114 ± 14 118 ± 20 0.27
Diastolic BP (mm Hg) 64 ± 13 68 ± 10 70 ± 11 0.34
Hemoglobin (g/dL) 11.2 ± 1.2 11.2 ± 0.9 11.1 ± 1.4 0.76
Calcium (mg/dL) 8.75 ± 0.50 8.80 ± 0.47 8.88 ± 0.42 0.27
Phosphate (mg/dL) 5.0 ± 0.68 4.95 ± 0.73 5.0 ± 0.74 0.87
Alkaline phosphatase (IU/l) 138 ± 65 128 ± 103 124 ± 84 0.45
25-OH Vitamin D3 (nmol/l) 18 ± 14 17 ± 11 14 ± 11 0.29
Log [iPTH (pg/mL)] 2.40 ± 0.35 2.21 ± 0.36 2.12 ± 0.39 0.01
LDL-C (mg/dL) 102 ± 36 104 ± 33 103 ± 40 0.91
HDL-C (mg/dL) 35 ± 9 37 ± 10 38 ± 14 0.87
Triglycerides (mg/dL) 143 (112; 325) 149 (99; 354) 157 (112; 325) 0.67
Uric acid (mg/dl) 6.9 ± 1.1 6.7 ± 0.9 6.6 ± 0.7 0.53
CRP (mg/L) 10.6 (0.6, 31) 11 (0.6, 44) 13 (0.8, 80) 0.12
Albumin (g/L) 4.13 ± 0.28 3.90 ± 0.35 3.74 ± 0.33 0.05
nPCR (g/kg/d) 1.1 (0.9, 1.22) 1.1 (0.9, 1.25) 1.1 (0.9, 1.30) 0.86
Kt/Vurea 1.60 ± 0.14 1.58 ± 0.18 1.60 ± 0.17 0.90
ESA use (n, %) 77 (67%) 78 (66.6%) 83 (70.3%) 0.62
Calcitriol use (n, %) 79 (68.6%) 80 (68.3%) 82 (69.4%) 0.89
Ca-based phosphate binder use (n, %) 255 84 (73%) 81 (69.2%) 90 (76%) 0.58
Calcimimetic use (%) 0 0 0 –
Statin use (%) 0 0 0 –
Antihypertensive agents use (n, %) 57 (49.5%) 56 (47.8%) 62 (52.5%) 0.68
Aspirin/antiplatelet agents use (n, %) 77 (67%) 83 (71%) 85 (72%) 0.71
Abbreviations and deﬁnitions: AV, arteriovenous; PAD; peripheral arterial disease; BP, blood pressure; BMI, body mass index; ESA, erythropoiesis-
stimulating agent; hs-CRP, high-sensitivity C-reactive protein; Log iPTH, logarithm of serum intact parathyroid hormone; LDL-C, low-density
lipoprotein cholesterol; nPCR, normalized protein catabolic rate; statins, HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase
inhibitors.
Fig. 1 – Computed tomographic scan showing calciﬁcation of the arteriovenous ﬁstula (AVF) (a) and a non-calciﬁed AVF (b).
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Table 2 – Univariate and multivariate logistic regression analysis for arteriovenous ﬁstula calciﬁcation.
Parameter Univariate  Analysis Multivariate Analysis
HR; 95CI% p HR; 95CI% p
Age 1.04 (0.99–1.10) 0.06 1.06 (0.94–1.20) 0.30
Men 0.94 (0.31–2.81) 0.92
Dialysis vintage 0.98 (0.96–1.00) 0.16 1.03 (0.97–1.09) 0.36
Presence of Type 2 DM 16.61 (3.32–83.62) 0.001 7.39 (1.37–36.68) 0.18
Treatment with calcium-based phosphate binders 3.39 (2.40–5.56) 0.002 1.63 (1.32–2.99) 0.04
BMI 0.88 (0.76–1.00) 0.37
Systolic BP 0.98 (0.95–1.01) 0.24
Diastolic BP 0.98 (0.93–1.04) 0.66
LDL-cholesterol 1.00 (0.98–1.02) 0.73
HDL-cholesterol 1.00 (0.96–1.05) 0.72
Triglycerides 1.00 (0.99–1.03) 0.66
Hemoglobin 1.09 (0.67–1.78) 0.71
Albumin 0.25 (0.02–2.53) 0.24
Calcium 1.00 (0.23–4.31) 0.99
Phosphate 0.63 (0.24–1.62) 0.34
Log serum intact PTH 0.31 (0.05–1.92) 0.21
25-hydroxy vitamin D3 0.99 (0.98–1.01) 0.78
Sclerostin 6.60 (2.88–18.55) 0.003 0.26 (0.20–0.37) 0.03
Positive cardiovascular history 4.31 (1.07–17.31) 0.04 4.32 (1.04–18.51) 0.04
Uric acid 0.84 (0.44–1.59) 0.60
CRP 1.02 (0.97–1.07) 0.42
Alkaline phosphatase 1.00 (0.99–1.00) 0.35
Abbreviations and deﬁnitions: DM, diabetes mellitus; BMI, body mass index; BP, blood pressure; Log iPTH, logarythm of serum intact parathyroid
hormone; CRP, C-reactive protein.
serum sclerostin levels were shown to be associated with
decreased bone turnover, osteoblast number, bone mineral
density and microarchitecture in dialysis patients.7,11 More-
over, sclerostin has been demonstrated to be upregulated
during vascular smooth muscle cell calciﬁcation in vitro.8 This
in vitro data were conﬁrmed by an in vivo mouse model of
vascular calciﬁcation.14 Moreover, sclerostin has been demon-
strated in human aortic extracts by a comprehensive analysis
of extracellular space components comprising the vascular
proteome.15 Additionally, recent evidence indicates that Wnt
signaling is also involved in aortic valve calciﬁcation.16 More
recent studies demonstrate association of serum sclerostin
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Fig. 2 – Kaplan–Meier curve depicting patient survival according to tertiles of serum sclerostin levels.
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Fig. 3 – Kaplan–Meier curve depicting patient survival according to presence of arteriovenous ﬁstula calciﬁcation.
Table 3 – Univariate and multivariate logistic regression analysis for patient outcome.
Parameter Univariate  Analysis Multivariate Analysis
HR; 95CI% p HR; 95CI% p
Age 1.35  (1.09–1.64) 0.01 1.16 (1.01–1.33) 0.03
Men 1.56 (1.24 –2.92) 0.43 – –
Dialysis vintage 1.12 (0.99–1.26) 0.42 – –
Presence of type 2 DM 2.33 (1.45–3.92) 0.18 – –
Treatment with calcium-based phosphate binders 1.35 (1.21–1.99) 0.03 1.29 (1.27–1.45) 0.55
BMI 0.90 (0.84–0.98) 0.27 – –
Systolic BP 0.97 (0.93–1.02) 0.25 – –
Diastolic BP 0.89 (0.79–1.02) 0.10 0.93 (0.82–1.09) 0.11
LDL-cholesterol 0.99 (0.97–1.01) 0.66 – –
HDL-cholesterol 0.99 (0.92–1.06) 0.13 1.01 (0.99–1.03) 0.54
Triglycerides 1.00 (0.98–1.03) 0.89 – –
Hemoglobin 0.25 (0.11–0.57) 0.05 0.44 (0.19–0.95) 0.20
Albumin 0.39 (0.33–0.88) 0.025 0.51 (0.25–0.78) 0.04
Calcium 1.19 (0.70–3.83) 0.60 – –
Phosphate 1.25 (1.04–3.16) 0.67 – –
Log serum intact PTH 0.90 (0.66–1.01) 0.180 0.96 (0.91–1.04) 0.71
25-hydroxy vitamin D3 0.97 (0.90–0.99) 0.147 0.99 (0.94–1.08) 0.55
Sclerostin: Above vs below median 1.22 (1.19–1.65) 0.55 – –
Presence of PAD 1.59 (1.14–2.47) 0.47
Uric acid 0.49 (0.35–0.92) 0.03 0.57 (0.43–0.79) 0.07
CRP 1.01 (0.97–1.05) 0.59 – –
Alkaline phosphatase 0.98 (0.96 –1.01) 0.06 1.00 (0.99–1.03) 0.16
Presence of AV ﬁstula calciﬁcation by CT 5.26 (1.77–8.34) 0.02 2.30 (1.44–5.62) 0.03
Abbreviations and deﬁnitions: DM: diabetes mellitus; BMI: body mass index; BP: blood pressure; Log iPTH: logarythm of serum intact parathyroid
hormone; PAD: peripheral arterial disease; CRP: C-reactive protein; CT: computerized tomography.
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levels and different types of cardiovascular calciﬁcation17,18
and arterial stiffness.19
In the present work, patients who died in 24-months
follow-up had signiﬁcantly higher sclerostin levels at base-
line and patients with increasing serum sclerostin levels had
worse survival. These results were somewhat in contrast to
recent publications. Firstly, Viaene et al. demonstrated a ten-
dency to have a better survival with these sclerostin levels.20 In
addition, NECOSAD trial revealed that patients in the highest
sclerostin tertile had a signiﬁcantly lower risk of cardiovas-
cular death and for all-cause mortality within 18 months
compared with patients of the lowest tertile.21 However, the
authors stated that the association of sclerostin levels with
outcome was  less pronounced for long-term cardiovascular
mortality and absent for noncardiovascular mortality.21 The
present work and Viaene’s study are comparable in a way
that signiﬁcances were lost in fully adjusted models includ-
ing bone-speciﬁc alkaline phosphatase in Viaene’s work20
and arteriovenous ﬁstula calciﬁcation in the present work.
In contrast, NECOSAD trial results showed an independent
association with sclerostin and cardiovascular outcomes even
after adjustments for alkaline phosphatase.21 However, more
recently, Gonc¸alves et al. published their work regarding a
hemodialysis patients’ cohort, which was followed during a
ten-year period.22 They reported that high serum sclerostin
levels were associated with cardiovascular mortality in preva-
lent dialysis patients, independent of diabetes and age, in a
competing analysis approach, supporting the results of the
present work.22 The reasons for the discrepancies between the
three cohorts – including the present work, remain specula-
tive. Use of different assays to measure serum sclerostin levels
and statistical issues involving power might have signiﬁcant
contribution.21
Some potential mechanisms could be proposed to explain
this variability. First, it might be speculated that, like in
the bone, osteocyte-like cells in the vascular wall may pro-
duce sclerostin after they become embedded in mineralized
matrix and might exhibit a negative feedback signal on
osteoblasts.13 The ﬁnal result might be a defensive response
to block the Wnt  pathway in order to reduce ossiﬁcation and
avoid further progression in whom vascular calciﬁcation is
well established and severe,14,19 suggesting accompanying
higher sclerostin levels in patients with more  cardiovascular
calciﬁcation burden17,18 that might contribute to overall
mortality. In the present work, the ﬁnding of sclerostin levels
as an independent determinant of arteriovenous ﬁstula
calciﬁcation supports this hypothesis (Table 2) and might
explain the survival disadvantage in patients with high
serum sclerostin levels, representing increased demands
to mitigate further progression of vascular calciﬁcation.
Signiﬁcant correlation of peripheral serum and bone marrow
plasma sclerostin levels23 suggests that sclerostin of bone or
vascular tissue origin, may circulate in the blood and might
play an important role in the cross talk between bone and the
vessels.23 Second, study patients with sclerostin levels above
median value had increased age, lower albumin levels, and
more  cardiovascular history which are described as strong
mortality-predicting markers previously in patients with
chronic kidney disease.24,25 Third, these patients also had
increased frequency of arteriovenous ﬁstula calciﬁcation that
was one of the independent factors predicting survival in this
work (Table 2). Similarly, a recent work reported association
of vascular access calciﬁcation with increased mortality risk,
and Cox regression analysis conﬁrmed that vascular access
calciﬁcation was an independent mortality predictor.26 This
ﬁnding was well in agreement with previous studies reporting
vascular calciﬁcation as a risk factor for mortality in patients
with end stage renal disease.27–29 The increased levels of scle-
rostin concentrations in patients with arteriovenous ﬁstula
calciﬁcation than patients without, also suggests sclerostin
as a part of a feedback loop targeting to impede advanced
mineralization of calcifying vascular tissue.3,8
Calciﬁcation of the arteriovenous ﬁstula does not always
imply a poor function. The prevalence of arteriovenous ﬁs-
tula calciﬁcation detected by spiral CT was 40% in a Spanish
study.30 The presence of calciﬁcations in the arteriovenous ﬁs-
tula is related to the length of time the patient has been on
hemodialysis and the duration of the arteriovenous ﬁstula.30
The function of a well-developed arteriovenous ﬁstula with no
stenosis and suitable for chronic hemodialysis is not affected
by the presence of calciﬁcations that are diagnosed by spiral
CT.30
Limitations of the present work include relatively small
sample size and short term follow-up. Furthermore, serum
sclerostin level may change over time in dialysis patients, and
sclerostin concentration was used at only a single time in the
outcome analysis. This factor decreases the potential predic-
tive power of individual serum level. Our data conﬁrm the
previous study by Viaene et al.20 that serum sclerostin level
was not an independent predictor of mortality in maintenance
hemodialysis patients. However, study data need conﬁrma-
tion with further clinical studies with longer follow-up and
more participants. Additionally, data regarding bone histo-
morphometry was unfortunately unavailable and we  were not
able to establish the link among sclerostin, histologic bone
parameters and vascular calciﬁcation (arteriovenous ﬁstula in
this case).
In conclusion, growing evidence implicate that sclerostin
might be an important element in the vascular calciﬁca-
tion and bone metabolism in patients with chronic kidney
disease. Additional investigations are needed to elucidate
whether changes in sclerostin levels also translate into clini-
cal parameters affecting morbidity and mortality in patients
on maintenance hemodialysis.
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